COVID-19: EU, Remdesivir supply contract: need to be reviewed?
-Almost no effect was seen in WHO clinical trials-
Remdesivir:
WHO clinical trial results:
In a clinical trial (clinical trial) of the World Health Organization (WHO), the US Gilead Sciences antiviral drug “remdesivir” was shown to have “a result that has little effect on reducing mortality.”
Supply contract with EU:
On October 8, the EU signed a supply contract for Gilead and Remdesivir on behalf of 27 member countries and 10 partner countries, including the United Kingdom.
Need to review:
The European Union (EU) has signed a 1 billion euro ($ 1.2 billion) supply contract with Gilead Sciences.
There is a “view that it needs to be reviewed”.
European Medicines Agency (EMA): Janis Natosis
European Commission
Explaining why the EU hastened a deal with Gilead,
Based on WHO clinical trial results
The contract needs to be reviewed.
Said.
EU spokesman:
He declined to comment on “Is the EU informed about the outcome of the WHO trial at the time of the contract with Gilead?”
He also declined to comment on “whether to renegotiate the price agreed with Gilead.”
Newsweek Japan version
https://www.newsweekjapan.jp/stories/world/2020/10/euwho.php
Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir)
FOSTER CITY, Calif.–(BUSINESS WIRE)–
Gilead Sciences (Nasdaq: GILD) and the European Commission
today signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir),
the first antiviral drug proven to be effective for the treatment of COVID-19 in the European Union (EU).
First COVID-19 treatment recommended for EU authorisation
Remdesivir
is the first medicine against COVID-19 to be recommended for authorisation in the EU.
Data on remdesivir
were assessed in an exceptionally short timeframe through a rolling review procedure,
an approach used by EMA during public health emergencies to assess data as they become available.
European Medicines Agency
https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation
Remdesivir price curbs in India make COVID-19 treatment more affordable: GlobalData – Express Pharma